Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

NCT04662528 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped suspended

Conditions

Severe Hypertriglyceridemia

Interventions

DRUG: Placebo
DRUG: MAT9001 (omega-3 pentaenoic acid)

Sponsor

Matinas Biopharma, Inc

Collaborators

[object Object]